@dr.alo's peptide warning, fact-checked

What did @dr.alo actually say?

Dr. Vos, a self-described Cornell-educated cardiologist, delivered a blunt verdict: peptides are a money grab. The core argument was that "there are no peptides or things you can buy that are going to prolong your life," and that even BPC-157, widely considered the most-studied therapeutic peptide, is "not proven to do anything" because there are "no randomized human outcome trials." He also flagged real safety concerns about injecting unregulated compounds and closed with a reasonable bottom line: stick to FDA-approved medications.

The tone was dismissive rather than analytical, which matters. A cardiologist saying peptides won't extend your life is a narrow claim presented as a broad condemnation. Those are very different scientific statements, and conflating them does the audience a disservice.

Does the science back this up?

Partly, but the framing is too blunt to be fully accurate. The claim that there are zero human randomized controlled trials showing benefit for peptides is largely correct for most compounds in this category, but the science isn't as empty as Dr. Vos implies.

BPC-157 has a legitimate preclinical research base. Animal studies, including work by Sikiric et al. published repeatedly in Current Pharmaceutical Design and Journal of Physiology-Paris, show consistent effects on tissue repair, gut integrity, and angiogenesis in rodent models. A 2021 review by Chang et al. in Biomedicines summarized mechanisms across dozens of animal studies. None of this is human trial data, and that gap is real. But saying the compound "is not proven to do anything" ignores a meaningful body of mechanistic and preclinical evidence that justified the research in the first place.

For peptides like GHK-Cu, there is published in vitro and some human skin research. Ipamorelin and CJC-1295 have phase I and II human data on growth hormone secretion, though long-term outcome data is thin. The landscape is uneven, not barren.

What did they get wrong (or right)?

Dr. Vos got the regulatory and safety point right. Most peptides sold through wellness channels are not FDA-approved drugs. They are often sold as research chemicals or through compounding pharmacies operating in legal gray zones. Injecting unverified compounds carries genuine risks: contamination, mislabeling, and unknown pharmacokinetics. That warning is responsible and accurate.

Where he went wrong is in conflating "no large human RCT" with "not proven to do anything." Those are different standards. Preclinical evidence exists and informs legitimate ongoing research. His characterization that "the guy that owns it has run a few tests and none of them showed any kind of benefit" is factually inaccurate. Sikiric's group has published over 100 peer-reviewed papers on BPC-157 derivatives, and while the research origin warrants scrutiny, calling the results uniformly negative is simply wrong.

He also did not distinguish between different peptides at all. MK-677, for example, is an oral ghrelin mimetic with actual phase II human trial data on body composition and GH secretion (Nass et al., 2008, Journal of Clinical Endocrinology and Metabolism). Semax has Russian clinical trial data on cognitive and neurological applications. Grouping all peptides as identical scams is intellectually lazy, even if the broader skepticism is warranted.

What should you actually know?

The honest answer is that the evidence base for peptide therapy is genuinely immature for most compounds, and that immaturity cuts both ways. It does not prove they work, but it also does not prove they are worthless. For most people spending money on peptides based on social media claims and bro-science forums, the skepticism Dr. Vos offers is probably useful. The problem is that oversimplification in the other direction, dismissing everything without nuance, can also push people away from areas of legitimate emerging research.

What is well-established: no peptide currently sold through consumer channels has FDA approval for the indications being marketed. Compounded versions of these compounds are not equivalent to pharmaceutical-grade research preparations. Safety monitoring when using any injectable compound outside of clinical supervision is essentially nonexistent. Those are the facts that should drive consumer caution, not a cardiologist's confident but imprecise dismissal.

• If you are considering peptide therapy, the conversation starts with a licensed provider who can assess risk, not an Instagram video in either direction.
• Human trial data for most therapeutic peptides is sparse. That is a legitimate scientific gap, not proof of fraud.
• FDA approval is a high bar that many legitimate compounds have not yet cleared. That does not make them dangerous or effective. It means the evidence is incomplete.